4DS MEMORY LIMITED — Director's Dealing 2019

Jan 20, 2019

Appendix 3Y Change of Director’s Interest Notice

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Introduced 30/9/2001.
Name of entity	4DS Memory Limited
ABN	43 145 590 110

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

irector for the purposes of section 205G of	the Corporations Act.
Name of Director	Mr David McAuliffe
Date of last notice	29 November 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.		Concept Biotech Pty Ltd (director related entity)David Jerimiah McAuliffe (trustee and beneficiary)
Date of change		21 January 2019
No. of securities held prior tochange		DirectDavid McAuliffe2,521,839 fully paid ordinary sharesIndirectConcept Biotech Pty Ltd2,498,812 fully paid ordinary sharesDavid Jerimiah McAuliffe7,501,188 fully paid ordinary shares
Class		Fully paid ordinary shares
Number acquired		Indirect – 555,555
Number disposed		-
Value/Considerationincludes brokerage/gstNote: If consideration is non-cash, providedetails and estimated valuation		$25,000.00

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after	Direct
change	David McAuliffe
	2,521,839 fully paid ordinary shares
	Indirect
	Concept Biotech Pty Ltd
	2,498,812 fully paid ordinary shares
	David Jerimiah McAuliffe
	8,056,743 fully paid ordinary shares
Nature of change	Issue of fully paid ordinary shares on the same terms and
Example: on-market trade, off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation in	conditions as the placement announced on 13 November 2018and as per shareholder approval granted on 18 January 2019.
buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

sclosedinthis part.
Detail of contract	N/A-
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

**art 3– **+Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearancewas required?	N/A
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2